Intellia Therapeutics, Inc. (NTLA) Stock Rating Reaffirmed by Barclays PLC
Intellia Therapeutics, Inc. (NASDAQ:NTLA)‘s stock had its “buy” rating reissued by equities research analysts at Barclays PLC in a research note issued on Sunday.
A number of other equities research analysts also recently issued reports on the stock. Credit Suisse Group boosted their price target on shares of Intellia Therapeutics from $24.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday. Jefferies Group LLC set a $42.00 price target on shares of Intellia Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 31st. Leerink Swann boosted their price target on shares of Intellia Therapeutics from $29.00 to $37.00 and gave the company an “outperform” rating in a research note on Tuesday, October 31st. They noted that the move was a valuation call. Zacks Investment Research raised shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Finally, Wedbush reissued an “ourperform” rating and issued a $25.00 price target (down from $29.00) on shares of Intellia Therapeutics in a research note on Wednesday, September 27th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $30.17.
Intellia Therapeutics (NASDAQ NTLA) opened at $21.94 on Friday.
Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Tuesday, October 31st. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.06. The business had revenue of $7.30 million for the quarter, compared to the consensus estimate of $5.83 million. Intellia Therapeutics had a negative net margin of 215.92% and a negative return on equity of 28.01%. The business’s revenue was up 49.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.22) EPS. research analysts anticipate that Intellia Therapeutics will post -1.68 EPS for the current year.
TRADEMARK VIOLATION WARNING: This article was first reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.watchlistnews.com/intellia-therapeutics-inc-ntla-stock-rating-reaffirmed-by-barclays-plc/1679988.html.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Moloney Securities Asset Management LLC purchased a new stake in Intellia Therapeutics during the 3rd quarter worth approximately $306,000. Dynamic Technology Lab Private Ltd purchased a new stake in Intellia Therapeutics during the 2nd quarter worth approximately $167,000. California State Teachers Retirement System increased its stake in Intellia Therapeutics by 79.0% during the 2nd quarter. California State Teachers Retirement System now owns 25,143 shares of the company’s stock worth $402,000 after buying an additional 11,100 shares during the period. The Manufacturers Life Insurance Company increased its stake in Intellia Therapeutics by 451.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,224 shares of the company’s stock worth $212,000 after buying an additional 10,825 shares during the period. Finally, State Street Corp increased its stake in Intellia Therapeutics by 52.0% during the 2nd quarter. State Street Corp now owns 164,798 shares of the company’s stock worth $2,638,000 after buying an additional 56,363 shares during the period. 47.77% of the stock is currently owned by hedge funds and other institutional investors.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.